Completed PHASE3 INTERVENTIONAL 2-arm NCT00035477

Efficacy and Safety of Azimilide for the Treatment of Patients With Atrial Fibrillation

Sponsor: Forest Laboratories

Interventions Azimilide Dihydrochloride Placebo

Updated 7 times since 2017 Last updated: Sep 30, 2011 Started: Sep 30, 2000 Primary completion: Oct 31, 2003 Completion: Oct 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00035477, this PHASE3 trial focuses on Atrial Fibrillation and remains completed. Sponsored by Forest Laboratories, it has been updated 7 times since 2000, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Sep 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Forest Laboratories

Data source: Forest Laboratories

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Allentown, United States , Auburn, United States , Beaver, United States , Beloit, United States , Burlingame, United States , Calgary, Canada , Charleston, United States , Cincinnati, United States , Cleveland, United States , Dallas, United States and 65 more locations